Expert opinion of the European Tuberculosis Laboratory Initiative core group members for the WHO European Region.
Автоматизированная технология амплификации нуклеиновых кислот в режиме реального времени для быстрого и одновременного выявления туберкулеза и устойчивости к р...ифампицину: система Xpert MTB/RIF.
Программное заявление.
more
Strengthening of SDB teams through refresher trainings and regular simulation exercises/drills
Continue social mobilization and community engagement through mobile cinema and community awareness sessions
Procure and preposition additional PPE kits
This document has been developed to provide training and guidance on how to integrate a human rights approach in mental health and related areas, based on international human rights instruments, in particular the UN Convention on the Rights of Persons with Disabilities (CRPD).
In light of the decline in new Ebola cases, strategies are now needed to scale down the activities and bed capacities in Ebola care facilities. These facilities include Ebola treatment units, community care centres, Ebola treatment centres and isolation centres. The Governments of Guinea, Liberia an...d Sierra Leone; WHO; CDC; ICAN and UNICEF have jointly developed this rapid guidance and checklist to assist national governments and partners as they begin this process. This rapid guidance pertains to protecting the safety and repurposing of infrastructures and resources previously used for the Ebola outbreak to care for Ebola patients.
more
African Evaluation Journal
ISSN: (Online) 2306-5133, (Print) 2310-4988
Background: For some years, non-governmental organisations (NGOs) and civil society have
become increasingly involved in the fight against the HIV/AIDS pandemic in Africa. But even
though their role is well appreciated, the...ir actions are perceived as ineffective because of a lack
of monitoring and evaluation capacity.
Objective: This paper aims to describe local HIV/AIDS NGOs’ involvement in evaluation and
the characteristics of this involvement.
more
The pre-clinical pipeline shows more innovation and diversity, with 252 agents being developed to treat WHO priority pathogens.
However, these products are in the very early stages of development and still need to be proven effective and safe. The optimistic scenario, the report indicates, is for... the first two to five products to become available in about 10 years.
more
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr...am-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli, can cause severe and often deadly infections that pose a particular threat for people with weak or not yet fully developed immune systems, including newborns, ageing populations, people undergoing surgery and cancer treatment.
The report highlights a worrying gap in activity against the highly resistant NDM-1 (New Delhi metallo-beta-lactamase 1), with only three antibiotics in the pipeline. NDM-1 makes bacteria resistant to a broad range of antibiotics, including those from the carbapenem family, which today are the last line of defence against antibiotic-resistant bacterial infections.
more